International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Amgen Announced the United States Food and Drug Administration (FDA) Approval of AMJEVITA™

Psoriasis News Amgen Blog Graphic

Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.

Categories

Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Albert Duvetorp, MD, PhD

Medical Adherence in Topical Agents in the Context of Psoriasis Patients

Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics

Also Read

Sotyktu

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.